menu
    • menu

    Company profile for Isofol Medical

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Isofol Medical AB (publ.) is a biotech company working with the development of the cancer drug, arfolitixorin. Arfolitixorin is a new drug candidate that Isofol is primarily developing to treat colorectal cancer (CRC) – the third most common type of cancer and one for which there is a substantial need for more effective drugs. Isofol’s development work with arfolitixorin is also targeting so-called “rescue therapy” aft...
    Isofol Medical AB (publ.) is a biotech company working with the development of the cancer drug, arfolitixorin. Arfolitixorin is a new drug candidate that Isofol is primarily developing to treat colorectal cancer (CRC) – the third most common type of cancer and one for which there is a substantial need for more effective drugs. Isofol’s development work with arfolitixorin is also targeting so-called “rescue therapy” after high-dose chemotherapy with methotrexate in conjunction with osteosarcoma (bone cancer). Other potential uses for arfolitixorin also includes the treatment of pancreatic cancer, breast cancer, stomach cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Isofol MedicalSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Biotech Center, Arvid Wallgrens Backe 20 SE-413 46 Gothenburg
    Telephone
    Telephone
    +46 (0)31 7972280
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://isofolmedical.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023
    CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023

    28 Nov 2022

    // FINANCEYAHOO

    https://finance.yahoo.com/news/ceo-ulf-jungnelius-leave-isofol-170700225.html

    FINANCEYAHOO
    28 Nov 2022
    Share Share
    Final data from the AGENT study confirms topline results
    Final data from the AGENT study confirms topline results

    25 Nov 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/final-data-from-the-agent-study-confirms-topline-results-301687096.html

    PRNEWSWIRE
    25 Nov 2022
    Share Share
    Isofol Medical AB (publ) publishes interim report, January-September 2022
    Isofol Medical AB (publ) publishes interim report, January-September 2022

    11 Nov 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/isofol-medical-ab-publ-publishes-interim-report-januaryseptember-2022-301675286.html

    PRNEWSWIRE
    11 Nov 2022
    Share Share
    Isofol appoints nomination committee ahead of the Annual General Meeting 2023
    Isofol appoints nomination committee ahead of the Annual General Meeting 2023

    03 Nov 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/isofol-appoints-nomination-committee-ahead-of-the-annual-general-meeting-2023-301667823.html

    PRNEWSWIRE
    03 Nov 2022
    Share Share
    Isofol reports data from the AGENT study
    Isofol reports data from the AGENT study

    07 Sep 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/isofol-reports-data-from-the-agent-study-301619102.html

    PRNEWSWIRE
    07 Sep 2022
    Share Share
    Isofol provides update on the AGENT study
    Isofol provides update on the AGENT study

    31 Aug 2022

    // CISION

    https://news.cision.com/isofol-medical-ab--publ-/r/isofol-provides-update-on-the-agent-study,c3623994

    CISION
    31 Aug 2022
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search